权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Neuronanomedicine

神经纳米医学

基本信息

批准号：
8529879
负责人：
Howard E Gendelman
金额：
$ 2.5万
依托单位：
AMERICAN SOCIETY FOR NANOMEDICINE I
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-03-15 至 2014-03-14
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8529879
关键词：
Affect American Animal Testing Applied Research Area Basic Science Behavior Disorders Bioethics Biology Blood - brain barrier anatomy Brain Brain region Cells Clinical Clinical Trials Communicable Diseases Community Healthcare Data Development Diagnosis Diagnostic Discipline Disease District of Columbia Drug Industry Drug Targeting Educational process of instructing Engineering Environment Equilibrium Ethics Evolution Fostering Future Gender Glean Goals Health Personnel Human Industry Inflammatory Institutes Intellectual Property Journals Laboratories Laboratory Animals Lead Leadership Learning Location Malignant Neoplasms Measures Medicine Mentorship Metabolic Diseases Minority Monitor Nanotechnology Nerve Degeneration Nervous system structure Neurologist Neurosciences Neurosurgeon Oral Outcome Outcomes Research Patients Pharmaceutical Preparations Pharmacologic Substance Pharmacology Pharmacy (field)Physicians Positioning Attribute Principles of law and justice Psychiatrist Publications Publishing Quality Control Regenerative Medicine Request for Proposals Research Research Personnel Rest Role Safety Science Scientist Seasons Societies Solutions Students Technology Testing Therapeutic Toxic effect Training Translations Vascular Diseases Work addiction base bioimaging career clinical toxicology commercialization disorder prevention experience implantation improved infancy innovation insight interest meetings multidisciplinary nanobiology nanofabrication nanoimaging nanomaterials nanomedicine nanosurgery nanotoxicology nervous system disorder new technology next generation novel outreach posters product development programs protein misfolding public health relevance relating to nervous system repaired social success symposium web page web site

项目摘要

DESCRIPTION (provided by applicant): Neuronanomedicine is a new research field defined as the development and translation of nanotechnology for diagnosis and treatment of degenerative, inflammatory, infectious, vascular, addictive, behavioral and metabolic disorders of the nervous system. The research discipline is interdisciplinary and in its infancy. Hurdles need be overcome for success to be realized that improve known blood brain barrier restrictions, nanotoxicologies, inefficient drug targeting to diseased brain regions and in reaching specific neural subcellular compartments. These all pose significant challenges to the field. To facilitate successful research outcomes we plan to bring together scientists from divergent backgrounds engaged in neuronanomedicine to present research findings that will help define the field while also facilitating opportunities for trainees to directly engage in currnt and future discussions. The American Society for Nanomedicine (ASNM) has taken a leadership role by focusing its 2013 meeting to the multifaceted discipline of neuronanomedicine. The ASNM is well positioned to assume this role as the society's goals since its 2008 inception has rested in clinical translation of nanotechnologies. Such goals will be fostered in an open forum discussion that will include, but is not limited to, bioethics, safety an toxicity, intellectual property, and product commercialization. A major focus for the conference is in bringing early career investigators into the field of translational neuronanomedicine. ASNM's emphasis on innovation and practicality of approaches for speedy translation parallels the conference goals on merging divergent disciplines and approaches to facilitate collaborative research from product development to laboratory and animal testing and ultimately to human clinical trials. The proposal while led by an experienced physician-scientist, Dr. Howard Gendelman, takes advantage of a highly seasoned broad-disciplined board. Overall, the focus on the nervous system represents an evolution of ASNM leadership and a further change in direction for the meeting. It will enable new directives in the field to keep abreast with needs an research scope in nanotechnology.

描述（由申请人提供）：神经纳米医学是一个新的研究领域，定义为纳米技术的开发和转化，用于诊断和治疗神经系统的退行性、炎症、感染性、血管性、成瘾性、行为和代谢性疾病。该研究学科是跨学科的，并且还处于起步阶段。要取得成功，需要克服障碍，改善已知的血脑屏障限制、纳米毒理学、针对患病大脑区域和到达特定神经亚细胞区室的低效药物。这些都对该领域提出了重大挑战。为了促进成功的研究成果，我们计划将来自不同背景的从事神经纳米医学的科学家聚集在一起，展示研究成果，这将有助于定义该领域，同时也为学员提供直接参与当前和未来讨论的机会。美国纳米医学会 (ASNM) 发挥了领导作用，将 2013 年会议的重点放在神经纳米医学的多方面学科上。 ASNM 完全有能力承担这一角色，因为该协会自 2008 年成立以来的目标一直致力于纳米技术的临床转化。这样的目标将是在公开论坛讨论中促进，其中包括但不限于生物伦理学、安全性和毒性、知识产权和产品商业化。会议的一大焦点是将早期职业研究人员带入转化神经纳米医学领域。 ASNM 强调快速翻译方法的创新和实用性，这与会议的目标是一致的，即融合不同的学科和方法，以促进从产品开发到实验室和动物测试以及最终到人体临床试验的协作研究。该提案由经验丰富的医师兼科学家 Howard Gendelman 博士领导，并利用了经验丰富、学科广泛的董事会。总体而言，对神经系统的关注代表了 ASNM 领导层的演变以及会议方向的进一步转变。它将使得该领域的新指令能够跟上纳米技术研究范围的需求。